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Antioxidant properties of amniotic membrane: novel observations from a pilot 26 
study 27 
Abstract: 28 
Introduction 29 
Amniotic membrane (AM) is used to manage various debilitated ocular surface 30 
conditions. The impact of oxidative stress and free radicals on the ocular surface is 31 
increasingly being recognised.  Hyaluronic acid (HA) has anti-inflammatory 32 
properties and is abundantly present in AM. In this in vitro pilot study we investigated 33 
AM¶Vpotential for intrinsic free radical scavenging properties. 34 
   35 
Methods 36 
Strips of AM were incubated in sealed tubes with hydrogen peroxide (H2O2). After 37 
being sonicated, uptake of reactive oxygen species (ROS) was measured by the 38 
Amplex Red Hydrogen Peroxide/Peroxidase assay. 1630kDA HA was used for 39 
comparison. 40 
 41 
Results 42 
There was uptake of ROS by all AMs samples, which decreased with increasing 43 
concentrations of H2O2. Mean ROS uptake for 5 different AMs at 1 hour was 44 
significantly greater for 50uM (83%; SD 11.7, SEM 5.23) compared to 100uM (67%; 45 
SD 20.48, SEM 9.16; p=0.028, 95% CI (2.8,29.2)). The HA comparison group 46 
showed similar uptake and trend.   47 
 48 
Conclusion 49 
This pilot study demonstrates that AM is able to remove ROS IURPLWV¶HQYLURQPHQW50 
Demonstrating total antioxidant capacity in AM provides evidence for use as a free 51 
radical scavenger. The antioxidant properties of AM and the contribution from HA 52 
require more research.  53 
 54 
Word Count: 195 55 
56 
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Introduction 57 
Oxidative stress is increasingly being recognised as the common inflammatory 58 
cellular pathway in ocular surface disease.1,2 It is the result of the imbalance between 59 
total antioxidant capacity and reactive oxygen species.3 The healthy eye has a variety 60 
of protective antioxidant defences, including the constituents of the normal tear film.1 61 
It follows that any chronic ocular surface injury can exhaust these protective defences 62 
and cause local free radical damage. For example, glutathione has been shown to be 63 
depleted in the tear film of patients with keratoconus.4 Oxidative stress can happen at 64 
both an exogenous and endogenous level to the cornea, and has recently been 65 
described in pterygia, corneal dystrophies, dry eyes, trauma, a host of inflammatory 66 
conditions and chemical injuries.2,5,6 67 
 68 
Amniotic membrane (AM) is often used to reconstruct the debilitated ocular surface, 69 
including after chemical injury.7-9 It has been shown to facilitate epithelial healing and 70 
analgesia, when used either as a patch dressing, or in extract form, as a suspension or 71 
drops. 10-12 However, the reported benefits of AM in chemical injury have not always 72 
being replicated in other studies.13-17 73 
 74 
Hyaluronic acid (HA), a multifunctional glycosaminoglycan and component of extra 75 
cellular matrices, has been shown to be abundantly present in AM, and a recent study 76 
demonstrated a covalent complex of heavy chain-hyaluronic acid (HC-HA) as the 77 
active component responsible, in part, for anti-inflammatory and anti-scarring 78 
actions.18 HA in the AM stroma has been shown to play a role in entrapping 79 
inflammatory cells, so reducing further damage to ocular tissue.19 Studies have shown 80 
that high and low molecular weight HA have different biological effects. For 81 
example, high molecular weight HA has been shown to be anti-inflammatory, and can 82 
protect the cornea from oxidative stress associated with preservatives in ophthalmic 83 
preparations (such as BAK and EDTA) and UV-related free radical damage.20-27 84 
Alternatively, low molecular weight HA has been shown to be generated by oxidative 85 
fragmentation (such as due to peroxide) and to accumulate with inflammation.28-30 86 
 87 
Total antioxidant capacity has previously been described in amniotic fluid.31 We 88 
wondered if the same was true of AM and hypothesised that some of the benefits of 89 
AM may be due to intrinsic free radical scavenging antioxidant properties. In this in 90 
4 
 
vitro pilot study AM was exposed to various concentrations of hydrogen peroxide (as 91 
an exogenous source of free radicals). HA was used as a control group to compare the 92 
magnitude of any uptake of H2O2.  93 
94 
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Methods: 95 
This study was approved as part of a non-substantial amendment to utilise surplus 96 
AM tissue from a previous project by the West of Scotland Ethics Committee and 97 
Research and Development Office. [See R&D Ref: WN08OP219; Ethics Ref: 98 
08/S0709/98] Briefly, AM was collected from human placentas delivered after 99 
caesarean section following written informed consent. The placentas were thoroughly 100 
rinsed with balanced salt solution containing streptomycin, penicillin, neomycin and 101 
amphotericin. The amnion was separated from the chorion by blunt dissection, cut 102 
into one square inch pieces and stored at -80°C in a 50/50 mixture of glycerol and 103 
Roswell Park Memorial Institute medium supplemented with 10% FCS, penicillin-104 
streptomycin and L-glutamine (Invitrogen, Paisley, UK). 105 
 106 
Prior to use, AM samples which had been stored at -80oC were defrosted and washed 107 
4 times with phosphate buffered saline (PBS). 1cm by 0.5cm strips of AM were cut 108 
and used throughout. The AM strips were incubated in the dark at 37oC with 300uL of 109 
H2O2. The tissue was incubated in sealed tubes to prevent evaporation. Incubation 110 
times were for 1 hour at 15 minute intervals. The H2O2 solutions were freshly 111 
prepared from a 30% stock solution (Sigma). 112 
 113 
Control tubes with no AM were included at each concentration of H2O2 for every 114 
assay. There was no change in the control values during the experiment indicating that 115 
there had been no degradation or evaporation of the peroxide. This value was 116 
FRQVLGHUHGWREHWKHµLQLWLDOFRQFHQWUDWLRQ¶LQWKHVXEVHTXHQWFDOFXODWLRQVRIXSWDNH 117 
 118 
After incubation, the tissues were sonicated in an MSE sonicator for 1 minute in 119 
300uL PBS/0.5% Triton X and spun in a microfuge for 10 minutes at 4000rpm. The 120 
supernatant was evaluated for Reactive oxygen species (ROS) by the Amplex Red 121 
Hydrogen Peroxide/Peroxidase method (Invitrogen, Paisley, UK). This procedure was 122 
done in duplicate for all tested measurements. The uptake was calculated by 123 
subtracting the concentration of H2O2 left in the supernatant from the initial 124 
concentration. 125 
 126 
 127 
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The Amplex Red Hydrogen Peroxide/Peroxidase Assay is a sensitive, one-step assay 128 
that uses the Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) to detect 129 
hydrogen peroxide or peroxidase activity. It has been used to detect H2O2 released 130 
from biological samples, enzyme-coupled reactions and is ultrasensitive even when 131 
H2O2 is in excess. In the presence of peroxidase, the Amplex Red reagent reacts with 132 
H2O2 in a 1:1 stoichiometry to produce the red-fluorescent oxidation product, 133 
resorufin. This reaction has been used to detect as little as 10 picomoles of H2O2 in a 134 
ȝ/YROXPH. [For more information, see www.invitrogen.com] 135 
 136 
The differences in uptake at different concentrations of H2O2 were tested statistically 137 
using a paired t-test in Minitab (version 15). 138 
 139 
We wanted to work with small volumes of AM and H2O2 to make it clinically relevant 140 
to the ocular tissues. In light of this, we chose to standardise our samples to 1cm by 141 
0.5cm strips. By weighing several pieces of AM on standard laboratory scales, we 142 
found that our small samples had an average weight of 4.5mg. We then wished to 143 
estimate the concentration of hyaluronic acid in our small strips. Published studies 144 
have quoted a concentration of 0.45mg of hyaluronic acid per gram on wet AM 145 
tissue.18 We were then able to calculate that the hyaluronic acid content was 146 
approximately 2ug per strip. Hyaluronic acid Streptococcus equi. 1630 kDa (Sigma 147 
Cat. No. 53747) was chosen as the comparative equivalent as AM predominantly 148 
contains high molecular weight long chain hyaluronic acid. Using the conditions 149 
described above, 2ug hyaluronic acid was incubated with various concentrations of 150 
H2O2 and resultant uptake was calculated. In the same assay 3 different AM samples 151 
replaced hyaluronic acid so that comparison of any uptake could be made. 152 
 153 
154 
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Results: 155 
There was uptake of ROS by the AM for all tested H2O2 concentrations within the 156 
first hour. The level of uptake decreased with increasing concentrations of H2O2. To 157 
illustrate this effect, samples from one individual AM consistently had 70% removal 158 
of ROS for 50uM H2O2, 45% removal for 100uM and 18% removal for 200uM after 159 
incubation for 1 hour. 160 
 161 
One hour analysis of 7 AM samples at 50uM had a mean uptake of 82.6% (minimum 162 
70%, median 82%, maximum 100%, SD 9.8). One hour analysis of 5 AM samples at 163 
100uM had a mean uptake of 67% (minimum 45%, median 67%, maximum 95%, SD 164 
20.48). When we compared matched samples from 5 different AMs, mean ROS 165 
uptake at 1 hour was significantly greater at 83% (SD 11.7, SEM 5.23) for 50uM 166 
compared to 67% (SD 20.48, SEM 9.16) for 100uM (p=0.028, 95% CI (2.8,29.2)). 167 
The mean difference was 16% (based on the 5 paired data values for analysis). 168 
[Figure 1]  169 
 170 
Figure 2 illustrates the percentage uptake in two individual AM samples within the 171 
first hour of exposure. For 50uM H2O2 there was an average 55% uptake at 15 172 
minutes, 80% uptake at 30 minutes and 91% uptake at 60 minutes. For 100uM H2O2 173 
uptake at 15 minutes was 65%, at 30 minutes uptake was 87% and at 60 minutes it 174 
was 86%. These results provide further confirmation of uptake, but also demonstrate 175 
biological variability even within the same AM.  176 
 177 
In the hyaluronic acid comparison group, the uptake of H2O2 at 1 hour for the 50uM 178 
and 100uM concentrations was in the same range as for 3 different AMs sampled. 179 
Average uptake at 50uM H2O2 showed a trend towards higher uptake than at 100uM 180 
H2O2 (53% uptake vs 50.9% uptake).  This was lower than the uptake measured in the 181 
AMs (53% vs 69.9% for 50uM H2O2 and 50.9% vs 68.3% for 100uM H2O2).  The 182 
sample size (n=3) was too small to perform meaningful statistical analysis, but did act 183 
as an appropriate comparison group for the magnitude of the uptake. [Table 1] 184 
 185 
The accuracy of all these results was confirmed by duplication of testing and also by 186 
testing sealed controls which contained equivalent H2O2 without presence of AM. 187 
There was no reduction of H2O2 in these controls.188 
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Discussion: 189 
Studies have demonstrated that AM suppresses myofibroblastic differentiation, 190 
suppresses matrix metalloproteinase expression in the stroma, and can modulate the 191 
immune response by absorbing OLYHLQIODPPDWRU\DQGLPPXQHFHOOVLQWRLWV¶VWURPD192 
and render them into apoptosis.32-35 Rabbit model studies have evaluated the use of an 193 
immediate AM patch following an alkali wound and have demonstrated promotion of 194 
wound healing by inhibiting both proteinase activity and polymorphonuclear 195 
leucocyte infiltration.36  196 
 197 
We have demonstrated uptake of peroxide by all samples of AM, which increased 198 
over time, but appeared to plateau at 1 hour. The uptake was less at the greater 199 
concentrations, and was statistically significant between the 50uM and 100uM at one 200 
hour for 5 different AMs7KLVFRXOGSRLQWWRDVDWXUDWLRQHIIHFWZKHUHWKHWLVVXH¶V201 
ability to absorb the peroxide is overwhelmed by the higher concentrations of free 202 
radicals. If the antioxidant capacity of the AM was depleted by injurious agents, then 203 
the resultant oxidative stress would continue in the clinical setting, leading to further 204 
cellular damage. This overwhelming saturation would render the AM ineffective, and 205 
could contribute in part to the reported variability and failure of AM 206 
transplantation.13,16,17 The uptake in the HA comparison group was of a similar 207 
magnitude to the AM group. However, the average results suggest that AM had a 208 
greater potency for removing H2O2 than HA alone. 209 
 210 
Free radicals and the cornea 211 
Our pilot study suggests that AM is able to scavenge reactive oxygen species. This 212 
total antioxidant capacity has been previously described in the evaluation of amniotic 213 
fluid.31 The antioxidant capacity of AM may be an additional mode of action for the 214 
surgeon to utilise as they seek to reconstruct the debilitated ocular surface. Free 215 
radical damage is increasingly being identified as a cellular component of corneal 216 
disease.37 Exposure to exogenous free radicals has been shown to cause mitochondrial 217 
DNA damage in corneal epithelial cells.38 Corneal fibroblasts have been shown to 218 
decline with age in response to oxidative stress. Through measuring antioxidant 219 
enzymes in primary cultured corneal fibroblasts from patients and healthy subjects, 220 
recent research has implicated oxidative damage induced by decreased catalase 221 
expression as a causative factor in the pathogenesis of corneal dystrophies.39 222 
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Oxidative stress has also been shown to keep Pax6 in a chronic wound state, and the 223 
effect on subcellular localisation, signalling and gene dosage effect contributes to 224 
aniridia-related keratopathy.40 Oxidative stress can also be exogenous, and the source 225 
could be due to external factors such as surface toxicity from multiple medications. 226 
Intrinsic free radical presence has been reported in topical and intracameral 227 
ophthalmic preparations, independent of preservatives or pH.41-43 Low grade chronic 228 
oxidative stress could explain residual inflammation in vulnerable ocular surfaces 229 
even when using long term unpreserved medications.  230 
 231 
An increased awareness of the role of free radicals in corneal disease may lead to 232 
future treatment strategies using antioxidant agents. For example, HA has been shown 233 
to decrease oxidative DNA damage induced by EDTA and BAK in human corneal 234 
epithelial cells.20,21 Antioxidant capacity could be an additional benefit to those 235 
described with early intervention with AM in the acute stages of an ocular chemical 236 
injury.44,45 Topical and oral YLWDPLQ&LVDOUHDG\XVHGIRULWV¶DQWLR[LGDQWproperties in 237 
this scenario. This relationship between oxidative stress and antioxidant protection is 238 
already being actively explored in anterior segment diseases such as glaucoma, 239 
cataract and posterior segment disease such as age-related macular degeneration. 46-48 240 
 241 
Limitations: 242 
We acknowledge that this was a pilot study with small numbers which could affect 243 
the statistical analysis of our results. However, our original premise was to perform a 244 
proof of principle study to evaluate if AM had antioxidant capacity. Variability in our 245 
results may have been due to effect of storage and processing of the samples. This 246 
clinical concern has been raised previously in the literature, and is the motivation for 247 
the development of a reproducible biosynthetic amniotic membrane which retains the 248 
properties of the human tissue.49 Variability in AM has been suggested as the reason 249 
for failure of treatment in ocular surface reconstruction. We did not measure the 250 
breakdown products of HA, and so our study does not allow direct comparison of the 251 
uptake of peroxide between the AM and the HA. However, it does act as a reasonable 252 
control regarding the magnitude of the uptake, and does provide a basis for future 253 
research. 254 
 255 
256 
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Conclusion: 257 
This pilot study demonstrates that amniotic membrane is able to remove ROS from 258 
LWV¶HQYLURQPHQW'HPRQVWUDWLQJWRWDODQWLR[LGDQWFDSDFLW\LQamniotic membrane 259 
provides evidence for use as a free radical scavenger. An increased awareness of the 260 
role of free radicals in corneal disease may lead to treatment strategies utilising 261 
antioxidant agents derived from hyaluronic acid or amniotic membrane. The role of 262 
hyaluronic acid and the antioxidant properties of amniotic membrane require further 263 
research.264 
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Legend: 415 
 416 
Figure 1: 417 
Graph showing spread of percentage uptake of hydrogen peroxide by 5 different 418 
amniotic membranes at 1 hour, consistently demonstrating decreased uptake with 419 
stronger concentrations. Mean ROS uptake for 5 AMs at 1 hour was significantly 420 
greater for 50uM (83%) compared to 100uM (67%, p=0.028). 421 
 422 
Figure 2: 423 
Graph showing average percentage uptake of hydrogen peroxide by 2 different 424 
amniotic membranes at 15 minute intervals in the first hour of exposure, 425 
demonstrating variability within individual membranes, and a plateau effect by 1 426 
hour. 427 
 428 
Table 1:  429 
Comparison table of hyaluronic acid group results demonstrating similar, but 430 
increased uptake of ROS with different 3 AMs compared to hyaluronic acid (HA) at 1 431 
hour. 432 
